Insights from leaders at top biopharma sponsors and world-class research institutions
Episodes
with Jason Coloma · CEO, Maze Therapeutics
Jason Coloma, CEO of Maze Therapeutics, explains how his team moved beyond statistical genetic associations to uncover the true mechanism behind APOL1-mediated kidney disease — a condition that disproportionately affects Black communities — and why the genetics-driven platform that worked in oncology is only now being applied seriously to nephrology.
Precision Medicine Got Kidney Disease Wrong — Until Now
with Jason Coloma
36 min
Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible
with Dr. Ken Sharlin
38 min
Why Serotonin Isn't Outdated, Our Thinking Is
with Dr. Jacob Jacobsen
40 min
Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian
with Dr. Lara Shirikjian
42 min
Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health
with Sonia Prashar
8 min read
The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients
with Dr. Craig Erickson
9 min read
Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs
with Dr. Laxminarayan Bhat
38 min
The 20-Year Industry Secret: Redefining Neurodegenerative Treatment
with Dr. Gabriel Vargas
53 min
One Mechanism, Three Conditions: A New Direction in Neurological Treatment
with Cuong Do
46 min
Why Clinical Trial Speed Kills Success — And What Top Sponsors Do Instead
with Dr. Steve Brannan
62 min
Innovation and Hope in Alzheimer's Care with Ram Mukunda
with Ram Mukunda
40 min
Challenges & Opportunities in Neuro Drug Development
with Matthew Leoni
44 min
Why a Daily Pill May Be Five Times Better Than Alzheimer's Antibodies
with Steven Gourlay
49 min
Nose to Brain: The New Class of Mental Health Drugs That Bypass the Bloodstream Entirely
with Shawn Singh
47 min
Keep It Simple: Srini Rao on the Engineering Mindset Behind Psychedelic Drug Development
with Srinivas Rao
50 min
Why Beckley Psytech Is Developing the Next Generation of Psychedelics
with Cosmo Feilding-Mellen
42 min
Patient-Informed Clinical Trial Development with Victoria DiBiaso
with Victoria DiBiaso
34 min
